Derek B Allison1, Rajni Sharma1, Morgan L Cowan1, Christopher J VandenBussche1,2. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
OBJECTIVES: Telomerase activity can be detected in up to 90% of urothelial carcinomas (UC). Telomerase activity can also be detected in urinary tract cytology (UTC) specimens and indicate an increased risk of UC. We evaluated the performance of a commercially available antibody that putatively binds the telomerase reverse transcriptase (hTERT) subunit on 500 UTC specimens. STUDY DESIGN: Unstained CytospinTM preparations were created from residual urine specimens and were stained using the anti-hTERT antibody (SCD-A7). Two algorithms were developed for concatenating the hTERT result and cytologic diagnosis: a "no indeterminates algorithm," in which a negative cytology and positive hTERT result are considered positive, and a "high-specificity algorithm," in which a negative cytology and positive hTERT result are considered indeterminate (and thus negative for comparison to the gold standard). RESULTS: The "no indeterminates algorithm" and "high-specificity algorithm" yielded a sensitivity of 60.6 and 52.1%, a specificity of 70.4 and 90.7%, a positive predictive value of 39.1 and 63.8%, and a negative predictive value of 85.0 and 85.8%, respectively. CONCLUSIONS: A positive hTERT result may identify a subset of patients with an increased risk of high-grade UC (HGUC) who may otherwise not be closely followed, while a negative hTERT immunocytochemistry result is associated with a reduction in risk for HGUC.
OBJECTIVES: Telomerase activity can be detected in up to 90% of urothelial carcinomas (UC). Telomerase activity can also be detected in urinary tract cytology (UTC) specimens and indicate an increased risk of UC. We evaluated the performance of a commercially available antibody that putatively binds the telomerase reverse transcriptase (hTERT) subunit on 500 UTC specimens. STUDY DESIGN: Unstained CytospinTM preparations were created from residual urine specimens and were stained using the anti-hTERT antibody (SCD-A7). Two algorithms were developed for concatenating the hTERT result and cytologic diagnosis: a "no indeterminates algorithm," in which a negative cytology and positive hTERT result are considered positive, and a "high-specificity algorithm," in which a negative cytology and positive hTERT result are considered indeterminate (and thus negative for comparison to the gold standard). RESULTS: The "no indeterminates algorithm" and "high-specificity algorithm" yielded a sensitivity of 60.6 and 52.1%, a specificity of 70.4 and 90.7%, a positive predictive value of 39.1 and 63.8%, and a negative predictive value of 85.0 and 85.8%, respectively. CONCLUSIONS: A positive hTERT result may identify a subset of patients with an increased risk of high-grade UC (HGUC) who may otherwise not be closely followed, while a negative hTERT immunocytochemistry result is associated with a reduction in risk for HGUC.
Authors: Elenir B C Avritscher; Catherine D Cooksley; H Barton Grossman; Anita L Sabichi; Lois Hamblin; Colin P Dinney; Linda S Elting Journal: Urology Date: 2006-09-18 Impact factor: 2.649
Authors: Isaac Kinde; Enrico Munari; Sheila F Faraj; Ralph H Hruban; Mark Schoenberg; Trinity Bivalacqua; Mohamad Allaf; Simeon Springer; Yuxuan Wang; Luis A Diaz; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; George J Netto Journal: Cancer Res Date: 2013-10-11 Impact factor: 12.701
Authors: Christopher J VandenBussche; Srividya Sathiyamoorthy; Christopher L Owens; Frances H Burroughs; Dorothy L Rosenthal; Hui Guan Journal: Cancer Cytopathol Date: 2012-11-28 Impact factor: 5.284
Authors: Christopher L Owens; Christopher J Vandenbussche; Frances H Burroughs; Dorothy L Rosenthal Journal: Cancer Cytopathol Date: 2012-11-28 Impact factor: 5.284
Authors: Dorothy L Rosenthal; Christopher J Vandenbussche; Frances H Burroughs; Srividya Sathiyamoorthy; Hui Guan; Christopher Owens Journal: Cancer Cytopathol Date: 2012-11-28 Impact factor: 5.284